Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma 1

Interventions

Carboplatin 15Pemetrexed 8Paclitaxel 6pembrolizumab 5osimertinib 4atezolizumab 4Gemcitabine 4Erlotinib Hydrochloride 4entinostat 3durvalumab 3Cisplatin 3selpercatinib 2pralsetinib 2camrelizumab 2apatinib 2Vinorelbine 2Radiosurgery 2Nivolumab 2Injections 2Gefitinib 2Bevacizumab 2130-nm albumin-bound paclitaxel 2toripalimab 1taletrectinib 1sotorasib 1sintilimab 1repotrectinib 1pegylated granulocyte colony-stimulating factor 1patritumab 1necitumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thoracic Neoplasms × ficlatuzumab × Thoracic × Clear all
NCT01039948 2015-04-08

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

AVEO Pharmaceuticals, Inc.

Phase 1/2 Completed
203 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡